EVOTEARS eye drops

URSAPHARM Arzneimittel GmbH

Sale price £39.95 Regular price £50.00

Tax included. Shipping calculated at checkout.

EVOTEARS eye drops

pack size:3ml Dosage form:eye drop

EVOTEARS eye drops

EvoTears ® eye drops: Unique1 for dry eyes
• Effective and lasting protection against the evaporation of tears thanks to innovative ingredients
• Water-free, therefore no need for preservatives and other aids
• High yield and long range
• Dry eyes go e.g. g. by using the screen.

EVOTEARS eye drops

Effective protection against evaporation
If you suffer from dry eyes, in almost 60% of all those affected an impairment of the outermost oily layer of the tear, also known as the lipid (oil) phase, is the sole cause behind the clinical picture. 2This leads to premature evaporation of the tear film, which manifests itself in dry, burning or watery eyes. EvoTears ® replaces this lipid phase and has therefore proven itself in the treatment of the main cause of dry eyes, ie the lipid phase disorder.

The eye drops owe their effective effect and good tolerability to the innovative ingredient perfluorohexyloctane and their lack of water. Perfluorohexyloctane spreads very quickly over the tear and thus forms a protective layer over it. Premature evaporation is effectively counteracted and dry eyes, e.g. B. by intensive screen work, prevented. Since the substance has the same refractive index as the tear, vision is not affected. EvoTears® _Eye drops are characterized by a high yield - up to 280 drops per 3 ml content - and a low frequency of use.

Anhydrous Eye Drops for Dry Eyes
EvoTears ® eye drops are the first anhydrous drops developed to treat dry eyes. Being water-free brings decisive advantages: no pH value and therefore no need for pH stabilizers such as phosphates. Since germs cannot multiply without water, preservatives can be dispensed with despite the normal dropper bottle. The addition of emulsifiers is also superfluous, as it is not an oil-water mixture.


Step 1: Open the bottle
Remove cap. Once before the first use: remove and dispose of the sealing ring.

EVOTEARS eye drops

Step 2: Squeeze the bottle gently
Hold the bottle with the dropper tip pointing upwards and squeeze gently.

EVOTEARS eye drops

Step 3: Let the air flow in
Before the bottle is brought to the eye: turn the pressed bottle downwards with the dropper tip and then release the pressure immediately. Air flows into the bottle.

EVOTEARS eye drops

Step 4: Bring the bottle to the eye
Continue to hold the bottle with the dropper tip pointing downwards and slide it over the eye. Put one drop in each eye by gently squeezing the bottle and close the bottle.

EVOTEARS eye drops

Due to the special nature of the EvoTears ®eye drops, it is possible that you will hardly notice the drop in your eye. In this case, it is advisable to apply the drops in front of the mirror or have a second person observe the application until you get to know the feeling of the drops being distributed on the eye.

Dry eyes are one of the most common eye diseases. According to estimates, every 6th adult in Germany is affected. In most cases, a lipid phase disorder is involved in the disease. 2 T he increased evaporation and the destabilization of the tear film result in dry, burning or watery eyes. Also typical are pronounced symptoms in the morning, which improve over the course of the day.EVOTEARS eye drops

A lipid phase disorder is caused, among other things, by the intensive use of digital media such as PCs, smartphones and tablets. Drafts or air conditioning and unfavorable climatic conditions, e.g. B. cold stimulus, can also affect the lipid phase.

We often sit in front of small or large screens, professionally and privately, which puts a lot of stress on our eyes. The bright monitor light can cause overstimulation, and the blinking reflex is reduced when looking with concentration: instead of 20 times, we only blink about 5 times a minute. EVOTEARS eye dropsAs a result, the sebaceous glands in the eyelid, also called meibomian glands, produce less of the lipid (oil) phase. If this lipid-containing protective layer is missing, the tear film ruptures prematurely, evaporates and dry eyes occur.

Since EvoTears ® specifically replaces the lipid phase, it can prevent premature evaporation of the tear film. The water-free eye drops cover the tears like a protective coat and thus counteract dry eyes.


How often should I use EvoTears ® eye drops?
It is usually sufficient to use EvoTears ® eye drops two to four times a day. The ingredient perfluorohexyloctane forms an effective protective film that stays on the eye for a long time and protects the tear film from evaporation. EvoTears ® is very economical with up to 280 drops per 3 ml content. Thanks to the low frequency of use, the 3 ml bottle is sufficient for a long time. If a 4-times daily application is required, the range is 35 therapy days. When used twice a day, the bottle lasts for 70 days of therapy.

Why are the drops in the eye hardly noticeable?
Thanks to perfluorohexyloctane, EvoTears® has a significantly lower surface tension than water, which means that the drop spreads quickly. In addition, at only approx. 10 μl, it is significantly smaller than water-based eye drops, which have a volume of 30 to 50 μl. The small drop volume of EvoTears ® corresponds to the capacity of the conjunctival sac and therefore little or no liquid escapes from the eye. EvoTears ® has oil-like properties and feels like balm on the eye. For these reasons, the application is perceived as very pleasant.

What distinguishes EvoTears ® from conventional tear substitutes? At
EvoTears®These are eye drops with oil-like properties. Compared to most tear substitutes, they do not replace the aqueous part of the tear film, but rather the lipid-containing protective film that covers the aqueous phase and protects it from evaporation. In this way, EvoTears ® alleviates the symptoms, specifically tackles the lipid phase disorder and thus protects against dry eyes in the long term.

How long do EvoTears ® eye drops last after opening?
EvoTears ® eye drops can be used for six months after opening the bottle. Please note the opening date on the folding box.

Can I use EvoTears ® if I wear contact lenses?
If you wear contact lenses, you should not use EvoTears ® as there is insufficient data on compatibility with contact lenses.

Is EvoTears ® also suitable for use on dry and irritated eyes?
Dry and irritated eyes, which are accompanied by redness and painful or crusted eyelids, are often caused by meibomian gland dysfunction. In this case, the use of EvoTears ® OMEGA is recommended. The eye drops were specifically developed to alleviate the typical symptoms of lipid phase disorders caused by meibomian gland dysfunction. In addition to the ingredient perfluorohexyloctane, these eye drops contain omega-3 fatty acids, which are components of natural tear fluid.3 A lack of omega-3 is often associated with dry eyes 3 and can lead to tear film disorders and corneal damage.

What measures can help with dry eyes caused by screen work?
In addition to using EvoTears ® , the following behavioral measures can help to alleviate the symptoms of the so-called office eye syndrome:
• Remember to consciously blink more often in order to regularly moisten your eyes. A sticky note on the screen can serve as a reminder. To stimulate the production of tear fluid, take short breaks in which you blink quickly several times in a row.
• Give your stressed eyes a break more often. If possible, you should take a short break every hour at work, in which you do not look at the screen but instead look into the distance.
• Tired eyes need oxygen to regenerate. A short walk outdoors is ideal. If you are in closed rooms, airing them out several times a day will help.
• Try to reduce the use of digital media in your free time. Your eyes will be happy if you take a walk after a long day at work instead of streaming series. Even small changes in usage behavior ensure a pleasant relaxation of the eyes.

due to perfluorohexyloctane
2Tong L et al. Invest Ophthalmol Vis Sci, 2010. 51: 3449-3454
3 Walter, SD et al. Invest Ophthalmol Vis Sci. 2016. 57:2472-2478 Image